Why your first dose of Wegovy may not feel like it's working

Why the starting dose is built for your body, not the scales

The STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults over 68 weeks and recorded an average weight loss of around 15% at 2.4 mg semaglutide. That figure comes from a gradual titration that took roughly 16–20 weeks to reach the maintenance dose. The study was not measuring what happened in week one because week one was never going to be the story.

Semaglutide works by activating GLP-1 receptors that regulate appetite signals and slow gastric emptying. At 0.25 mg those effects are present but modest. The dose is low enough that your digestive system can adapt without the nausea or vomiting that a full therapeutic dose would cause if taken from the start. Think of it less as a slow lead-in and more as the medicine earning your trust before it gets to work.

By the time most patients reach 1.7 mg or 2.4 mg, the appetite reduction is usually far more noticeable. The full Wegovy dose schedule walks through what each step is intended to achieve and what signs suggest a titration is going well.

What 'not working' usually looks like at each early dose

The phrase gets used loosely. Sometimes it means no weight loss. Sometimes it means hunger is unchanged. Occasionally it means side effects are so mild the medicine feels inert. Each has a different explanation.

No weight loss after dose one is expected. The 0.25 mg starting dose rarely produces measurable scale change in four weeks, and that absence is not a sign the medicine will fail you long-term. Appetite effects at 0.5 mg are similarly gentle for many people; the 0.5 mg phase is still considered a titration step in most treatment plans. Hunger changes that some patients describe at 1 mg are more consistent, and the majority of people report clear appetite suppression only once they reach 1.7 mg or 2.4 mg.

Mild or absent side effects are not evidence of a faulty pen or an ineffective product. Some people tolerate semaglutide very well from the start. The absence of nausea does not mean the medicine is not acting, it means your GI system is adapting efficiently, which is a good outcome.

If you are at a dose that should be producing results and seeing nothing after 8–12 weeks, that is worth discussing with your prescriber. The NHS semaglutide guidance recommends clinical review rather than self-adjustment.

Factors that can slow early progress on Wegovy

Even at effective doses, a handful of real-world factors can blunt the response.

Calorie compensation is common and easy to miss. Wegovy reduces appetite, it does not eliminate the habit of eating. Some people eat less at main meals but graze more between them without noticing. Keeping a rough log for two weeks can make invisible calories visible. Your prescriber or a dietitian can help you find a pattern that works alongside the medicine rather than against it.

Hydration matters more than most people expect. GLP-1 medicines slow gastric emptying, which can reduce thirst cues. Mild dehydration is easy to confuse with persistent hunger, leading to eating when the body would have responded better to water.

Storage is a practical check worth making early. Wegovy pens should be kept refrigerated between 2 °C and 8 °C. A pen left out of the fridge for longer than the window stated in the Patient Information Leaflet may be less effective. If you are unsure whether your pen was stored correctly (perhaps it sat in a bag during a long journey) check the leaflet or contact your prescriber before using it. Pen storage questions are something our support team hears regularly.

There is also the question of injection technique. Injecting into scar tissue or a site used too recently can reduce absorption. Rotating between abdomen, thigh and upper arm, as described in the instructions, helps maintain consistent delivery each week. A question about technique is genuinely straightforward to ask; one our prescribers are happy to walk through.

When to talk to your prescriber rather than wait it out

Patience is warranted in the early titration weeks. But there are moments when waiting is not the right call.

If you are at 1.7 mg or 2.4 mg, following the plan consistently, and seeing no change in appetite or weight after two to three months, your prescriber needs to know. NICE's appraisal of semaglutide, TA875, notes that patients who do not achieve at least 5% weight loss after six months on their maintenance dose should have their treatment reviewed. Earlier conversations are better than waiting for that threshold.

Equally, contact your prescriber promptly if you experience severe or persistent stomach pain, especially if it radiates towards your back. This can be a sign of pancreatitis, which requires medical assessment, not a watchful wait at home.

For patients who reached 2.4 mg but feel the ceiling is too low, the 2.4 mg not working page covers the evidence on higher doses in detail, including the 7.2 mg option now approved by the MHRA, with 2.7 mg representing one of the intermediate steps in that extended range. And if you are weighing Wegovy against other treatments, the weight-loss treatment overview sets out the licensed options available through a UK prescriber.

If you are not yet on treatment and want to understand whether Wegovy is clinically suitable for you, our prescribers review consultations the same day, a real clinician reads your answers, not a queue for software.